Serum zinc and risk of type 2 diabetes incidence in men: The Kuopio Ischaemic Heart Disease Risk Factor Study

Journal of Trace Elements in Medicine and Biology

Volumn 33, Issue , 2016, Pages 120-124

  Yary, Teymoor ^a   Virtanen, Jyrki K ^a   Ruusunen, Anu ^b   Tuomainen, Tomi Pekka ^a   Voutilainen, Sari ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

C reactive protein; Serum zinc; Type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; INSULIN; SOMATOMEDIN BINDING PROTEIN 1; ZINC; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CONTROLLED STUDY; FINN (CITIZEN); FOLLOW UP; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; ZINC BLOOD LEVEL; BLOOD; DIABETES MELLITUS, TYPE 2; FINLAND; HEART MUSCLE ISCHEMIA; HOMEOSTASIS; INFLAMMATION; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK FACTOR;

BIOMARKERS; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FINLAND; FOLLOW-UP STUDIES; HOMEOSTASIS; HUMANS; INCIDENCE; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RISK FACTORS; ZINC;

EID: 84951063249     PISSN: 0946672X     EISSN: 18783252     Source Type: Journal    
DOI: 10.1016/j.jtemb.2015.11.001     Document Type: Article

References (29)

1. Wallia A., Molitch M.E. Insulin therapy for type 2 diabetes mellitus. JAMA 2014, 311:2315-2325.
2. Dixon J.B. The global burden of obesity and diabetes. Minimally Invasive Bariatric Burgery 2015, 1-6. Springer.
3. Look AHEAD Research Group, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: Four-year results of the look AHEAD trial. Arch. Intern. Med., 170, 2010, 1566-1575.
4. Kazi T.G., Afridi H.I., Kazi N., Jamali M.K., Arain M.B., Jalbani N., Kandhro G.A. Copper, chromium, manganese, iron, nickel, and zinc levels in biological samples of diabetes mellitus patients. Biol. Trace Elem. Res. 2008, 122:1-18.
5. Huang L. Zinc and its transporters, pancreatic b-cells, and insulin metabolism. Vitam. Horm. 2014, 95:365-390.
6. Prasad A.S. Discovery of human zinc deficiency: its impact on human health and disease. Adv. Nutr. 2013, 4:176-190.
7. Petersson U., Östgren C.J., Brudin L., Brismar K., Nilsson P. Low levels of insulin-like growth-factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): the söderåkra cardiovascular risk factor study. Diabetes Metab. 2009, 35:198-205.
8. Rajaram S., Baylink D.J., Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions 1. Endocr. Rev. 1997, 18:801-831.
9. Li Y.V. Zinc and insulin in pancreatic beta-cells. Endocrine 2014, 45:178-189.
10. Rizzo M.R., Barbieri M., Marfella R., Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012, 35:2076-2082.
11. Jansen J., Karges W., Rink L. Zinc and diabetes-clinical links and molecular mechanisms. J. Nutr. Biochem. 2009, 20:399-417.
12. Yu Y., Cai Z., Zheng J., Chen J., Zhang X., Huang X., Li D. Serum levels of polyunsaturated fatty acids are low in chinese men with metabolic syndrome, whereas serum levels of saturated fatty acids, zinc, and magnesium are high. Nutr. Res. 2012, 32:71-77.
13. Ghasemi A., Zahediasl S., Hosseini-Esfahani F., Azizi F. Gender differences in the relationship between serum zinc concentration and metabolic syndrome. Ann. Hum. Biol. 2014, 41:436-442.
14. Salonen J.T. Is there a continuing need for longitudinal epidemiologic research: the kuopio ischaemic heart disease risk factor study. Ann. Clin. Res. 1988, 20:46-50.
15. Salonen J.T., Nyyssonen K., Korpela H., Tuomilehto J., Seppanen R., Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern finnish men. Circulation 1992, 86:803-811.
16. Lakka T.A., Venalainen J.M., Rauramaa R., Salonen R., Tuomilehto J., Salonen J.T. Relation of leisure-time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction in men. N. Engl. J. Med. 1994, 330:1549-1554.
17. Wallace T., Matthews D. The assessment of insulin resistance in man. Diabetic Med. 2002, 19:527-534.
18. Salonen J.T., Salonen R., Seppanen K., Kantola M., Suntioinen S., Korpela H. Interactions of serum copper, selenium, and low density lipoprotein cholesterol in atherogenesis. BMJ 1991, 302:756-760.
19. Koistinen H., Koistinen R., Selenius L., Ylikorkala Q., Seppala M. Effect of marathon run on serum IGF-I and IGF-binding protein 1 and 3 levels. J. Appl. Physiol. (1985) 1996, 80:760-764.
20. Prashad A.S. Zinc: an antioxidant and anti-inflammatory agent: role of zinc in degenerative disorders of aging. J. Trace Elem. Med. Biol. 2014, 28:364-371.
21. Taneja S.K., Jain M., Mandal R., Megha K. Excessive zinc in diet induces leptin resistance in wistar rat through increased uptake of nutrients at intestinal level. J. Trace Elem. Med. Biol. 2012, 26:267-272.
22. Rink L., Gabriel P. Extracellular and immunological actions of zinc. Biometals 2001, 14:367-383.
23. Al-Maroof R.A., Al-Sharbatti S.S. Serum zinc levels in diabetic patients and effect of zinc supplementation on glycemic control of type 2 diabetics. Saudi Med. J. 2006, 27:344-350.
24. Carneiro G., Laferrère B., Zanella M.T. Vitamin and mineral deficiency and glucose metabolism-a review. E-SPEN J. 2013, 8:e73-e79.
25. Brismar K., Fernqvist-Forbes E., Wahren J., Hall K. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J. Clin. Endocrinol. Metabol. 1994, 79:872-878.
26. Gibson J.M., Westwood M., Young R.J., White A. Reduced insulin-like growth factor binding protein-1 (IGFBP-1) levels correlate with increased cardiovascular risk in non-insulin dependent diabetes mellitus (NIDDM). J. Clin. Endocrinol. Metabol. 1996, 81:860-863.
27. Heald A., Cruickshank J., Riste L., Cade J., Anderson S., Greenhalgh A., Sampayo J., Taylor W., Fraser W., White A. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 2001, 44:333-339.
28. Heald A.H., Siddals K.W., Fraser W., Taylor W., Kaushal K., Morris J., Young R.J., White A., Gibson J.M. Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes. Diabetes 2002, 51:2629-2636.
29. Mohamed-Ali V., Pinkney I., Panahloo A., Cwyfan-Hughes S., Holly J., Yudkin J. Insulin-like growth factor binding protein-1 in NIDDM: relationship with the insulin resistance syndrome. Clin. Endocrinol. Oxford 1999, 50:221-228.